Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
telophase/cytokinesisanaphase
prophase prometaphase metaphase
Taxanes
(1) Targeting microtubules: TAXANES
MOLECULAR MECHANISM OF ACTION:
Taxanes make microtubules more stable
What do you think the consequences will
be for a dividing cell?
HOW TO KILL A MITOTIC CELL:
!dinCe"Mar Carmena
TAXANES (MICROTUBULE INHIBITORS)
EXAMPLE : TAXOL (PAXICLATEL)Isolated from the bark of the yew tree.
MOLECULAR MECHANISM OF ACTION
- Enhances stability of microtubules
- Mitosis blocks at the metaphase-anaphase transition.
Prolonged block results in cell death (apoptosis).
(Effect depends on drug concentration)
106 patients have been given taxol as part of their
chemotherapy regime world-wide.
ADVANTAGES
Very effective anti-tumor activity used in treatment of :
* ovarian cancer
* breast cancer
* non small cell lung cancer
DISADVANTAGES
-Severe adverse effects: neuropathies.
Microtubules are required for the transport of proteins and
vesicles along the axons of neurons.
- Development of resistance:
Tubulin mutations.
!dinCe"Mar Carmena
telophase/cytokinesisanaphase
prophase prometaphase metaphase
Vincas
(2) Targeting microtubules: VINCAS
MOLECULAR MECHANISM OF ACTION:
Vincas make microtubules less stable
What do you think the consequences will
be for a dividing cell?
HOW TO KILL A MITOTIC CELL:
!dinCe"Mar Carmena
VINCAS (MICROTUBULE INHIBITORS)
EXAMPLE : Vincristine, vinblastine
Isolated from Madagascar periwinkle.
MOLECULAR MECHANISM OF ACTION
Inhibits polylmerization of microtubules
Blocks mitotic progression.
Prolonged block results in apoptosis (cell death).
ADVANTAGES
- Vinblastin used very successfully in combination
chemotherapy of Hodgkin’s lymphoma.
- With the introduction of vincristine, the survival rate for
children with leukemia jumped from 20 to 80 percent.
DISADVANTAGES
- Severe adverse effects: neuropathies. Microtubules
are required for the transport of proteins and vesicles
along axon fibers.
!dinCe"Mar Carmena
telophase/cytokinesisanaphase
prophase prometaphase metaphase
Monastrol
(3) Targeting proteins associated with microtubules
(Kinesins): MONASTROL
MOLECULAR MECHANISM OF ACTION:
- Monastrol inhibits the activity of the protein Eg5.
- Eg5 is a kinesin (molecular motor). Its function is
to separate the poles of the spindle
What do you think the consequences will
be for a dividing cell?
HOW TO KILL A MITOTIC CELL:
!dinCe"Mar Carmena
KINESIN INHIBITORS
EXAMPLE : MONASTROL
Selected from a “library“ of small molecules.
MOLECULAR MECHANISM OF ACTION
- Inhibits the molecular motor Eg5, responsible for the
separation of centrosomes (spindle poles).
- Cells stop in mitosis with monopolar spindles and die by
apoptosis (cell death).
ADVANTAGES
- Only effect in dividing cells. No effect on interphase cells.
- No damage to neurons (no neuropathies).
DISADVANTAGES
- Development of resistance (Eg5 mutations).
!dinCe"Mar Carmena
telophase/cytokinesisanaphase
prophase prometaphase metaphase
BI 2536
Targeting proteins that control mitosis
(Kinases): BI 2536
MOLECULAR MECHANISM OF ACTION:
- BI 2536 inhibits the activity of Plk1.
- Plk1 is a kinase (enzyme). It has multiple functions
in mitosis: control of entry into mitosis, formation of
bipolar spindle, attachment of the chromosomes to
the spindle and cytokinesis.
What do you think the consequences will
be for a dividing cell?
BI 2536
HOW TO KILL A MITOTIC CELL:
!dinCe"Mar Carmena
KINASE INHIBITORS
EXAMPLE : BI 2536
Selected from a “library“ of small molecules.
MOLECULAR MECHANISM OF ACTION
- Inhibits the enzyme Polo kinase (PLK1),
required for: entry in to mitosis, formation of the mitotic
spindle, attachment of the chromosomes to the spindle
and cytokinesis.
- Cells stop in mitosis and die by apoptosis (cell
death).
ADVANTAGES
- Only effect in dividing cells. No effect on interphase cells.
- No damage to neurons (no neuropathies)
DISADVANTAGES
- Side effects: Bone marrow suppression.
Neutropenia
CLINICAL TRIALS: recurrent, metastatic solid tumors.
Prostate cancer, advanced pancreatic cancer, Breast
Cancer, Endometrial Cancer, Melanoma (Skin), Ovarian
Cancer.
!dinCe"Mar Carmena
telophase/cytokinesisanaphase
prophase prometaphase metaphase
MLN8237
Targeting proteins that control mitosis
(Kinases): MLN8237
MOLECULAR MECHANISM OF ACTION:
- MLN8237 inhibits the activity of Aurora A. Aurora
A is a kinase (enzyme). It is required to control entry
into mitosis and formation of bipolar spindle.
What do you think the consequences
will be for a dividing cell?
HOW TO KILL A MITOTIC CELL:
!dinCe"Mar Carmena
KINASE INHIBITORS
EXAMPLE : MLN8237
Selected from a “library“ of small molecules.
MOLECULAR MECHANISM OF ACTION
- Inhibits the enzyme Aurora kinase A, required
for: entry in to mitosis, formation of the mitotic spindle,
- Cells get delayed in mitosis with monopolar
spindles; they eventually divide aberrantly. Cell death.
ADVANTAGES
- Only effect in dividing cells. No effect on interphase cells.
-No damage to neurons (no neuropathies)
DISADVANTAGES
- Side effects: Bone marrow suppression.
Neutropenia
CLINICAL TRIALS:Advanced solid tumors
!dinCe"Mar Carmena
telophase/cytokinesisanaphase
prophase prometaphase metaphase
(5) Targeting proteins that control mitosis
(Kinases): ZM447439
MOLECULAR MECHANISM OF ACTION:
- ZM447439 inhibits the activity of Aurora B.
- Aurora B is a kinase (enzyme). It is required to
control attachment of the chromosomes to the
spindle and cytokinesis.
What do you think the consequences will
be for a dividing cell?
ZM447439
HOW TO KILL A MITOTIC CELL:
!dinCe"Mar Carmena
KINASE INHIBITORS
EXAMPLE : ZM447439
Selected from a “library“ of small molecules.
MOLECULAR MECHANISM OF ACTION
- Inhibits the enzyme Aurora kinase B. Aurora B
is required for multiple processes in mitosis: attachment of
the chromosomes to the mitotic spindle and cytokinesis.
- Cells get delayed in mitosis and fail cytokinesis,
generating polyploid cells. Cell death.
ADVANTAGES
- Only effect in dividing cells. No effect on interphase cells.
-No damage to neurons (no neuropathies)
DISADVANTAGES
- Side effects: Bone marrow suppression.
Neutropenia
CLINICAL TRIALS: ZM447439 is not used presently in
the clinic. Other Aurora B inhibitors are in clinical trials.
!dinCe"Mar Carmena